Catalyst Pharmaceuticals (CPRX) Earnings Date, Estimates & Call Transcripts $20.02 +0.14 (+0.70%) (As of 12:56 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 13EstimatedActual EPS (Aug. 7) $0.52 Beat By $0.13 Consensus EPS (Aug. 7) $0.39 Get Catalyst Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for CPRX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCPRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CPRX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. Catalyst Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20241$0.44$0.44$0.44 Q2 20241$0.55$0.55$0.55 Q3 20241$0.45$0.45$0.45 Q4 20241$0.48$0.48$0.48 FY 20244$1.92$1.92$1.92 Q1 20251$0.67$0.67$0.67 Q2 20251$0.50$0.50$0.50 Q3 20251$0.49$0.49$0.49 Q4 20251$0.54$0.54$0.54 FY 20254$2.20$2.20$2.20 Q1 20261$0.76$0.76$0.76 Q2 20261$0.61$0.61$0.61 CPRX Earnings Date and InformationCatalyst Pharmaceuticals last issued its earnings data on August 7th, 2024. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.13. The company earned $122.71 million during the quarter, compared to analyst estimates of $111.76 million. Catalyst Pharmaceuticals has generated $0.54 earnings per share over the last year ($0.54 diluted earnings per share) and currently has a price-to-earnings ratio of 36.8. Earnings for Catalyst Pharmaceuticals are expected to grow by 18.68% in the coming year, from $1.82 to $2.16 per share. Catalyst Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off prior year's report dates.Read More Catalyst Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/13/2024(Estimated)------- 8/7/2024Q2 2024$0.39$0.52+$0.13$0.71$111.76 million$122.71 million5/8/2024Q1 2024$0.31$0.31-$0.43$97.24 million$98.51 million 2/28/2024Q4 2023$0.45$0.49+$0.04$0.67$105.78 million$110.57 million 11/8/2023Q3 2023($0.26)($0.26)-($0.23)$100.17 million$102.69 million 8/9/2023Q2 2023$0.25$0.33+$0.08$0.33$92.77 million$99.58 million 5/10/2023Q1 2023$0.30$0.26($0.04)$0.26$83.04 million$85.37 million The death of Nvidia? (Ad)Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can.3/15/2023Q4 2022$0.21$0.22+$0.01$0.22$60.64 million$60.76 million 11/9/2022Q3 2022$0.19$0.20+$0.01$0.20$53.80 million$57.24 million 8/9/2022Q2 2022$0.17$0.20+$0.03$0.20$49.29 million$53.11 million 5/10/2022Q1 2022$0.14$0.12($0.02)$0.12$43.17 million$43.09 million 3/16/2022Q4 2021$0.12$0.09($0.03)$0.09$38.17 million$38.31 million 11/9/2021Q3 2021$0.10$0.10-$0.10$34.47 million$35.95 million 8/8/2021Q2 2021$0.10$0.11+$0.01$0.17$31.25 million$36.37 million 5/9/2021Q1 2021$0.09$0.07($0.02)$0.11$32.14 million$30.21 million 3/16/2021Q4 2020$0.09$0.11+$0.02$0.11$30.06 million$31.02 million 11/16/2020Q3 2020$0.10$0.11+$0.01($0.19)$31.22 million$29.32 million 8/10/2020Q2 2020$0.08$0.09+$0.01$0.09$28.97 million$29.61 million 5/11/2020Q1 2020$0.09$0.10+$0.01$0.10$31.68 million$29.14 million 3/16/2020Q4 2019$0.10$0.08($0.02)$0.07$30.00 million$30.12 million 11/12/2019Q3 2019$0.11$0.13+$0.02$0.13$33.19 million$30.90 million Catalyst Pharmaceuticals Earnings - Frequently Asked Questions When is Catalyst Pharmaceuticals's earnings date? Catalyst Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off last year's report dates. Learn more on CPRX's earnings history. What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, August, 7th. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $462.4 million. Did Catalyst Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Catalyst Pharmaceuticals (NASDAQ:CPRX) reported $0.52 earnings per share (EPS) to beat the analysts' consensus estimate of $0.39 by $0.13. Learn more on analysts' earnings estimate vs. CPRX's actual earnings. How much revenue does Catalyst Pharmaceuticals generate each year? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a recorded annual revenue of $434.48 million. How much profit does Catalyst Pharmaceuticals generate each year? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a recorded net income of $71.41 million. CPRX has generated $0.54 earnings per share over the last four quarters. What is Catalyst Pharmaceuticals's price-to-earnings ratio? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a trailing price-to-earnings ratio of 36.81 and a forward price-to-earnings ratio of 10.92. The price/earnings-to-growth ratio is 3.27. What is Catalyst Pharmaceuticals's EPS forecast for next year? Catalyst Pharmaceuticals's earnings are expected to grow from $1.82 per share to $2.16 per share in the next year, which is a 18.68% increase. More Earnings Resources from MarketBeat Related Companies: IDYA Earnings ANIP Earnings SYRS Earnings DRRX Earnings CUE Earnings ROIV Earnings ASND Earnings LEGN Earnings ITCI Earnings LNTH Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Nike’s Post-Earnings Drop Presents a Buying OpportunityMicron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season? This page (NASDAQ:CPRX) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | SponsoredKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.